Corneal verticillata after dual anti-epidermal growth factor receptor and anti-vascular endothelial growth factor receptor 2 therapy (vandetanib) for anaplastic astrocytoma Academic Article uri icon

Overview

MeSH Major

  • Astrocytoma
  • Brain Neoplasms
  • Corneal Diseases
  • Neoplasm Recurrence, Local
  • Piperidines
  • Quinazolines
  • Receptor, Epidermal Growth Factor
  • Vascular Endothelial Growth Factor Receptor-2

abstract

  • Vandetanib (ZD6474), a protein tyrosine kinase inhibitor with dual anti-EGFR and anti-vascular endothelial growth factor receptor 2 action, may have contributed to the formation of corneal verticillata in our patient. Inhibition of EGFR, which is involved with corneal epithelial cell migration and wound healing, may play a role in the pathogenesis underlying corneal vortex keratopathy and ocular surface conditions with significant epithelial turnover.

publication date

  • July 2009

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1097/ICO.0b013e3181922146

PubMed ID

  • 19512898

Additional Document Info

start page

  • 699

end page

  • 702

volume

  • 28

number

  • 6